01.29.25 -- How AI And Advanced Screening Are Reshaping Drug Discovery

Christopher Horan, Chief Technical Operations Officer at Artiva Biotherapeutics, joins Cell & Gene: The Podcast to explore the unique advantages of natural killer (NK) cells over T cells in autoimmune therapies. Host Erin Harris dives into why NK cells are ideal for scalable, ‘off-the-shelf’ treatments and highlights Artiva’s innovative “manufacturing first” strategy for production. Together, they uncover how these breakthroughs are shaping the future of cell therapy. Listen now!

Explore how to implement analysis using sedimentation velocity analytical ultracentrifugation to characterize AAV size distributions and multiple detection wavelengths to identify various fill states.

Could clinical trial compensation taxation be hindering the development of cutting-edge medications? Frontline clinical researchers say “yes,” and it’s more common than acknowledged.

In 2025, the FDA will require pharmaceutical companies to include diversity action plans for Phase II and pivotal studies, aiming to address how medications affect diverse populations.

Oren Ben-Yosef, Product Manager at Sartorius, highlights crucial criteria for selecting the right stem cell media and supplier, focusing on the significance of evaluating the quality systems of manufacturers.